FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer

The FDA approved the PARP inhibitor niraparib for use as a maintenance therapy for some women with advanced ovarian cancer.

Cancer Currents: An NCI Cancer Research Blog